69 results about "ATOPICLAIR" patented technology

A cellular constituent is lysed from, produced by and / or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and / or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response. Such methods include methods of treating, delaying the onset of or reducing the symptoms of one or more inflammatory conditions / diseases, including corporal or gastrointestinal inflammation, for example, Irritable Bowel Syndrome, Crohn's Disease, or colitis, and / or associated diseases such diabetes, asthma, multiple sclerosis, cancer, rheumatoid arthritis, gingivitis, atopic diseases, for example, hay fever, food allergies, eczema, rhinitis, dermatitis, conjunctivitis, atopic syndrome and keratosis pelaris, ocular inflammatory disease, strokes, cardiovascular disease, depression, atherosclerosis and hypertension, and comprise administering a composition comprising one or more natural and / or modified bacteria of the genus Bacteroides, and / or a cellular constituent lysed from, produced by, or isolated from one or more natural and / or modified bacteria from the genus Bacteroides, or a derivative thereof.

The present invention is related to a compound for the prevention and / or the treatment of allergy consisting of: at least one allergen antigenic determinant which is recognised by a B cell or an antibody secreted by a B cell of a non-atopic individual to said allergen, and at least one antigenic determinant of an antigen different from said allergen which triggers T cell activation.

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

Orally administered sodium cromoglycate has been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria and irritable bowel syndrome if it is presented such that the sodium cromoglycate becomes bioavailable within 10 minutes of exposure to intestinal fluid. The sodium cromoglycate may be presented as enteric-coated tablets or individually enteric-coated pellets or microgranules packaged with disintegrant in a ratio of at least 1.2:1 disintegrant:sodium cromoglycate (w:w). Optionally, the patients are first selected to have a total serum IgE level of at least 150 iu / ml.

A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, such as atopic dermatitis, and to the prevention and treatment of these allergic diseases.

This disclosure relates to multifunctional formulations, methods of manufacture and methods of use of natural topical and oral compositions to treat various dermatitis and pruritus conditions in mammals. In particular, this disclosure relates to a multifunctional topical pharmaceutical composition effective to treat dermatitis and associated pruritus comprising at least one natural plant extract TRPV1 antagonist, at least one natural plant extract is a TRPA1 antagonist, and a carrier. Also, in particular, this disclosure also relates to a multifunctional method to treat histamine induced and non-histamine dermatitis and associated pruritus in mammals from one or more of non-atopic and atopic dermatitis (AD), contact dermatitis, allergenic contact dermatitis (ACD), psoriasis, eczema, infestations, urticarial, nociceptive, neuropathic, neurogenic, psychogenic pruritus comprising treating with a composition comprising at least one natural plant extract TRPV1 antagonist, at least one natural plant extract is a TRPA1 antagonist, and a carrier.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and / or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders / other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

A method for developing a questionnaire, the method comprising the steps of developing a database of “n” questions and answers relating to skin or health conditions; correlating the answeres to the “n” questions to actual skin or health conditions; and selecting from the “n” questions a set of “m” key question, wherein “m” is less than “n”, and wherein the “m” questions provides within a predetermined statistical probability a population of people having a particular skin or health condition. In one embodiment, the method can be used for determining among a population of people a subset of people who are likely to have atopic skin dermatitis. In one embodiment, the correlating step can be achieved by use of a computer running a statistical analysis program.

Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.

The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scratching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.

The present invention relates to an antipruritic agent comprising a nociceptine antagonist as an active ingredient. The nociceptine antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scratching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

To provide An external skin agent that prevents onset of atopic skin inflammations and is low irritant to skin, which is characterized by including: 1) clay modified by a compound having a quaternary amino group; and 2) a polymer or copolymer that has a side chain including a structure similar to a biological component.

The present invention relates to a prophylactic and / or therapeutic agent for an allergic disease which contains a compound having an agonistic activity to EP3 receptor that is one of the prostaglandin E2 receptor subtypes. More specifically, a compound having an agonistic activity to EP3 receptor is effective in therapy of an allergic respiratory disease such as bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, and a selective agonistic compound can be expected to induce a more remarkable therapeutic effect.

The present invention relates to a pharmaceutical composition for treating atopy, which contains, as an active ingredient, neural stem cell-derived exosomes or a neural stem cell-conditioned medium containing neural stem cell-derived exosomes, and a method of treating atopy by administering the composition.

This invention relates to a method and composition for inducing allergen tolerance in a patient suffering from an atopic allergy or allergic asthma; hence reducing allergy symptoms in these patients.

The present invention relates to a cosmetic composition containing the snail derived from snails fed with red ginseng, which provides effects that are superior to those of slime from snails raised using typical methods in terms of wound healing, skin recovery, and alleviating atopy and skin irritation.

The present invention concerns a method of testing a subject thought to have or be predisposed to having asthma, allergy, atopic disease or atopic sensitization, which comprises the step of analyzing a biological sample from said subject for (i) detecting the presence of a mutation associated with the over-expression of the ORMDL3 gene, and / or (ii) analyzing the expression of the ORMDL3 gene; a use, for treating and / or preventing asthma, allergy, atopic disease or atopic sensitization in a subject, of a compound which specifically inhibits the expression of the ORMDL3 gene; and an in vitro method of selecting a compound, which can be useful for treating asthma, allergy, atopic disease or atopic sensitization, characterized in that said method comprises the steps of: (a) obtaining a cell expressing the ORMDL3 gene, (b) contacting said cell with at least one compound, (c) comparing the expression of the ORMDL3 gene in the cell between the steps a) and b), and (d) selecting the compound, which induces a lower level of expression of the ORMDL3 gene in the cell contacted to that compound.

Provided is a composition for atopy or psoriasis treatment including a liquid type plasma. More particularly, provided is a method for producing a liquid type plasma for preventing or treating atopic dermatitis or psoriasis, a pharmaceutical composition for preventing or treating atopic dermatitis or psoriasis using a liquid type plasma produced according to the method, and a method for preventing or treating atopic dermatitis or psoriasis using the liquid type plasma.

The present invention is directed to a method for diagnosing a subject as being or having a predisposition to being asthmatic. The present invention is also directed to methods of detecting whether a subject may be atopic by screening for genetic risk factors.

The present invention relates to a composition for alleviating atopic skin symptoms, containing, as active ingredients, high molecular weight poly-gamma-glutamic acid and low molecular weight poly-gamma-glutamic acid. The composition according to the present invention inhibits epidermal and transdermal moisture loss, removes keratinous materials, provides excellent skin soothing properties, and alleviates itching caused by drying, thereby providing a superior alleviation effect throughout atopic skin symptoms.

This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

The present invention is related to a compound for the prevention and / or the treatment of allergy consisting of:at least one allergen antigenic determinant which is recognized by a B cell or an antibody secreted by a B cell of a non-atopic individual to said allergen, andat least one antigenic determinant of an antigen different from said allergen which triggers T cell activation.

An ointment containing a compound represented by formula (I):[wherein R1 represents any group ofa group represented by the formula:—(CH2)4—S—CH2—CO2H,a group represented by the formula:—(CH2)4—S—CH2—CO2CH3,a group represented by the formula:—(CH2)4—C≡C—CO2H,a group represented by the formula:—CH2—S—(CH2)2—S—CH2—CO2H, anda group represented by the formula:—CH2—S—(CH2)4—CO2H],and an oleaginous base, is an ointment containing a compound which is effective for atopic symptoms, and is an ointment having low skin irritancy and excellent storage stability, thus, can be used as a pharmaceutical product effective for the pruritus caused by atopy or the like.

The invention discloses a capture probe and a kit for primary atopic disease related genes and application of the kit. The primary atopic disease related genes captured by the capture probe are selected from two or more of FLG, CDSN, DSG1, DSP, SPINK5, PLCG2, ADGRE2, TPSAB1, FOXP3, IL2RA, TGFBR1, TGFBR2, WAS, MALT1, CARD11, WIPF1, ARPC1B, DOCK8, CARMIL2, ERBIN, ZNF341, RAG1, RAG2, DCLRE1C, ADA, IL7RA, CHD7, LIG4, ZAP70, STAT3, STAT1, STAT5B, JAK1, IL4RA, IL6ST, IL6R and PGM3. The capture probe effectively improves the diagnosis efficiency of primary atopic diseases, and can provide a diagnosis basis for treatment. Mutation sites of the primary atopic diseases can be accurately and quickly detected.

The present specification discloses a biomarker for diagnosing skin cell damage caused by fine dust, a kit using the same, and a novel use of a composition comprising galangin as an active ingredient. Specifically, it is possible to conveniently check skin damage caused by fine dust by measuring and comparing the expression amounts of the biomarker in normal cells and cells damaged by fine dust. In addition, a composition of the present invention comprising galangin, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof as an active ingredient can normalize the gene expression of skin damaged by fine dust and promote differentiation of skin keratinocytes, thereby having a skin moisturizing or skin-barrier strengthening effect. Accordingly, since the composition can be used to prevent, treat, or alleviate skin diseases such as atopy, psoriasis, etc. the composition is useful.

The present invention provides a method of preparing a sorghum fermentation product having anti-inflammatory, anti-allergic and atopic skin-improving effects, comprising the steps of: obtaining sorghum powder by crushing sorghum (S10); hydrolyzing said sorghum powder, obtaining a sorghum solution (S20), adjusting the pH by adding a neutralizing agent to the sorghum solution (S30), sorbing the sorghum-adjusted sorghum solution using the enterobacteria or lactobacillus for obtaining a sorghum fermentation product (S40), and obtaining the sorghum fermentation powder (S50) by sterilizing, filtering and freeze-drying the sorghum fermentation product. In addition, the present invention provides cosmetic compositions containing sorghum fermentation products having anti-inflammatory, anti-allergic and atopic skin-modifying effects.

The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the ORAI1 gene. The invention also relates to the use of said si RNAs molecules in the treatment and / or prevention of an eye condition characterised by increased expression and / or activity of ORAI1 gene, preferably said eye condition is conjunctivitis and / or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.